80
Participants
Start Date
April 15, 2013
Primary Completion Date
July 24, 2021
Study Completion Date
July 24, 2021
dexamethasone
given intravenously or orally
vincristine sulfate
given intravenously
rituximab
given intravenously
clofarabine
given intravenously
cyclophosphamide
given intravenously
etoposide
given intravenously
aldesleukin
given subcutaneously
pegaspargase
given intravenously
methotrexate
given intrathecally or intravenously
mercaptopurine
given orally
cytarabine
given intrathecally or intravenously
mitoxantrone
given intravenously
teniposide
given intravenously
vinblastine
given intravenously
natural killer cell infusion
undergo allogeneic natural killer cell infusion
laboratory biomarker analysis
correlative studies
therapeutic hydrocortisone
given intrathecally
allogeneic hematopoietic stem cell transplantation
undergo allogeneic HSCT
CliniMACS
The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
St. Jude Children's Research Hospital, Memphis
Cook Children's Medical Center, Fort Worth
Rady Children's Hospital and Health Center, San Diego
Cookies for Kids' Cancer
OTHER
Assisi Foundation
OTHER
St. Jude Children's Research Hospital
OTHER